These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 1746012)

  • 1. An artefact related to the ratio of sample volume to the blood collection vial size which effects the APTTs of specimens taken to monitor heparin therapy.
    Ray MJ
    Thromb Haemost; 1991 Sep; 66(3):387-8. PubMed ID: 1746012
    [No Abstract]   [Full Text] [Related]  

  • 2. A low volume specimen container suitable for monitoring the aPTT of heparinized patients.
    Ray MJ; Carroll PA; Just SJ; Hawson GA
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):805-7. PubMed ID: 8292732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of inaccurate blood sample volume on prothrombin time (PT) and activated partial thromboplastin time (aPTT).
    Peterson P; Gottfried EL
    Thromb Haemost; 1982 Apr; 47(2):101-3. PubMed ID: 7101228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accuracy of drawing coagulation samples from heparinized arterial lines.
    Templin K; Shively M; Riley J
    Am J Crit Care; 1993 Jan; 2(1):88-95. PubMed ID: 8353585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples.
    van den Besselaar AM; Meeuwisse-Braun J; Bertina RM
    Thromb Haemost; 1990 Feb; 63(1):16-23. PubMed ID: 2339357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring heparin therapy by the activated partial thromboplastin time--the effect of pre-analytical conditions.
    van den Besselaar AM; Meeuwisse-Braun J; Jansen-Grüter R; Bertina RM
    Thromb Haemost; 1987 Apr; 57(2):226-31. PubMed ID: 3603414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of the activated partial thromboplastin time from a capillary (fingerstick) sample of whole blood. A new method for monitoring heparin therapy.
    Ansell J; Tiarks C; Hirsh J; McGehee W; Adler D; Weibert R
    Am J Clin Pathol; 1991 Feb; 95(2):222-7. PubMed ID: 1992612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of heparin on the activated partial thromboplastin time of the College of American Pathologists Survey specimens. Responsiveness, precision, and sample effects.
    Gawoski JM; Arkin CF; Bovill T; Brandt J; Rock WA; Triplett DA
    Arch Pathol Lab Med; 1987 Sep; 111(9):785-90. PubMed ID: 3632297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A frequent problem in the laboratory control of heparinization: contamination of blood specimens with exogenous heparin].
    Lämmle B; Noll G; Häuptli W; Tran TH; Luengo E; Lohri A; Ritz R; Duckert F
    Schweiz Med Wochenschr; 1984 Jun; 114(24):873-5. PubMed ID: 6740303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reliability of an intravenous intermittent access port (saline lock) for obtaining blood samples for coagulation studies.
    Arrants J; Willis ME; Stevens B; Gripkey L; Herman JA; Hernandez-Brooks L; Eaker JE
    Am J Crit Care; 1999 Sep; 8(5):344-8. PubMed ID: 10467472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drawing coagulation studies from arterial lines: an integrative literature review.
    Laxson CJ; Titler MG
    Am J Crit Care; 1994 Jan; 3(1):16-22; quiz 23-4. PubMed ID: 8118489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discard volumes necessary for clinically useful coagulation studies from heparinized Hickman catheters.
    Mayo DJ; Dimond EP; Kramer W; Horne MK
    Oncol Nurs Forum; 1996 May; 23(4):671-5. PubMed ID: 8735325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obtaining blood samples for coagulation studies from a normal saline lock.
    Powers JM
    Am J Crit Care; 1999 Jul; 8(4):250-3. PubMed ID: 10392225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Problems by using whole blood in heparin measurements.
    Talstad I
    Thromb Haemost; 1982 Apr; 47(2):177-81. PubMed ID: 7101239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Monitoring heparin therapy by thrombin time and activated partial thromboplastin time--a comparison].
    Lang M; Fey MF; Furlan M; Beck EA
    Schweiz Med Wochenschr; 1986 Nov; 116(48):1681-4. PubMed ID: 3798064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between arterial and venous activated partial thromboplastin time values in patients after percutaneous transluminal coronary angioplasty.
    Rudisill PT; Moore LA
    Heart Lung; 1989 Sep; 18(5):514-9. PubMed ID: 2528519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of aPTT in monitoring unfractionated heparin in children.
    Chan AK; Black L; Ing C; Brandão LR; Williams S
    Thromb Res; 2008; 122(1):135-6. PubMed ID: 17976694
    [No Abstract]   [Full Text] [Related]  

  • 18. [Is the activated partial thromboplastin time suitable for monitoring of thrombosis therapy with high-dose standard heparin?].
    Hürzeler C; von Felten A
    Schweiz Med Wochenschr; 1994 Apr; 124(17):712-9. PubMed ID: 8202668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of heparin therapy with the activated partial thromboplastin time and chromogenic substrate assays.
    Fey MF; Lang M; Furlan M; Beck EA
    Thromb Haemost; 1987 Oct; 58(3):853-5. PubMed ID: 3481140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A new test for monitoring heparin therapy].
    Camici M; Evangelisti L; Giordani R
    Minerva Med; 1998 Sep; 89(9):345-9. PubMed ID: 9856125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.